Connect Biopharma Holdings Ltd
CNTB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835268
No open-market purchases or sales by Connect Biopharma Holdings Ltd insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $33.1M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Connect Biopharma Holdings Ltd as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −5 vs. Q3 2022
- Shares held
- 11.1M
- −1.67M (−13.1%) vs. Q3 2022
- Total value
- $9.60M
- −$6.83M (−41.6%) vs. Q3 2022
- New holders
- 2
- 4 more added
- Sold out
- 7
- 8 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNTB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $33.1M |
| Q1 2026 | 41 | $32.4M |
| Q4 2025 | 29 | $23.9M |
| Q3 2025 | 16 | $2.45M |
| Q2 2025 | 17 | $2.40M |
| Q1 2025 | 13 | $1.56M |
| Q4 2024 | 14 | $4.37M |
| Q3 2024 | 11 | $4.23M |
| Q2 2024 | 12 | $4.52M |
| Q1 2024 | 12 | $6.87M |
| Q4 2023 | 15 | $8.40M |
| Q3 2023 | 14 | $8.22M |
| Q2 2023 | 16 | $11.7M |
| Q1 2023 | 16 | $10.9M |
| Q4 2022 | 20 | $9.60M |
| Q3 2022 | 25 | $16.4M |
| Q2 2022 | 29 | $13.0M |
| Q1 2022 | 28 | $53.4M |
| Q4 2021 | 29 | $87.4M |
| Q3 2021 | 20 | $467.5M |
| Q2 2021 | 16 | $372.4M |
| Q1 2021 | 26 | $284.6M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Connect Biopharma Holdings Ltd; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 994 | $0 | 0.00% | +91+10.1% | Added |
| Royal Bank of Canada | 80 | $0 | 0.00% | −72−47.4% | Reduced |
| Bank of America Corp | 12 | $10 | 0.00% | −81−87.1% | Reduced |
| FMR LLC | 83 | $72 | 0.00% | −4−4.6% | Reduced |
| Morgan Stanley | 359 | $311 | 0.00% | −7,732−95.6% | Reduced |
| JPMorgan Chase & Co | 5,560 | $4.00K | 0.00% | +2,490+81.1% | Added |
| Tower Research Capital LLC (TRC) | 10,398 | $9.00K | 0.00% | −5,812−35.9% | Reduced |
| UBS Group AG | 18,134 | $15.8K | 0.00% | +17,638+3,556.0% | Added |
| Geode Capital Management, LLC | 19,032 | $16.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 20,935 | $18.2K | 0.00% | +20,935 | New |
| Boothbay Fund Management, LLC | 26,867 | $23.3K | 0.00% | 00.0% | Unchanged |
| Ergoteles LLC | 44,297 | $38.4K | 0.00% | +44,297 | New |
| Renaissance Technologies LLC | 83,900 | $73.0K | 0.00% | +600+0.7% | Added |
| Citigroup Inc | 139,196 | $120.8K | 0.00% | −75,517−35.2% | Reduced |
| Ikarian Capital, LLC | 219,501 | $190.5K | 0.08% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 597,678 | $518.7K | 0.28% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 739,649 | $641.9K | 0.10% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,027,519 | $891.7K | 0.00% | −250,000−19.6% | Reduced |
| BlackRock Inc. | 1,125,262 | $976.5K | 0.00% | −301,166−21.1% | Reduced |
| Ra Capital Management, L.P. | 6,991,003 | $6.07M | 0.12% | 00.0% | Unchanged |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −613,931−100.0% | Sold out |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −450,000−100.0% | Sold out |
| CSS LLC | 0 | $0 | 0.00% | −38,721−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,497−100.0% | Sold out |
| Rocky Mountain Advisers, LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −397−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −258−100.0% | Sold out |